Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1982 4
1983 1
1984 4
1985 2
1986 1
1987 1
1988 1
1989 2
1990 1
1992 1
1995 3
1996 1
1997 1
1999 2
2000 1
2001 3
2002 1
2004 2
2005 5
2006 3
2007 5
2008 3
2009 5
2010 5
2011 4
2012 6
2013 2
2014 3
2015 2
2016 1
2017 2
2018 1
2021 3
2022 1
2023 1
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Removal of EpCAM-positive tumor cells during intraoperative blood salvage- A pivotal multicenter clinical study (REMOVE).
Meybohm P, Choorapoikayil S, Zinn S, Lindau S, Heiss M, Defosse J, Wittenmeier E, Ferner M, Kriegmair M, Westhoff N, Hottenrott S, Haas T, Kranke P, Zucker TP, Schnitzbauer A, Kluth L, Wappler F, Walossek N, Schuster M, Lotz A, Müll A, Schwab R, Mittler J, Betka I, Schoettler JJ, Kübler H, Seitz A, Lindhofer H, Zacharowski K; German Society of Anaesthesiology and Intensive Care (GSAIC) Trials Group. Meybohm P, et al. Among authors: lindhofer h. J Clin Anesth. 2025 Sep;106:111972. doi: 10.1016/j.jclinane.2025.111972. Epub 2025 Aug 13. J Clin Anesth. 2025. PMID: 40812168 Free article. Clinical Trial.
Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Ivasko SM, Anders K, Grunewald L, Launspach M, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Lode HN, Andersch L, Schulte JH, Eggert A, Hundsdoerfer P, Künkele A, Zirngibl F. Ivasko SM, et al. Among authors: lindhofer h. Front Immunol. 2023 Jan 9;13:1023206. doi: 10.3389/fimmu.2022.1023206. eCollection 2022. Front Immunol. 2023. PMID: 36700232 Free PMC article.
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A. Zirngibl F, et al. Among authors: lindhofer h. J Immunother Cancer. 2021 Jul;9(7):e002923. doi: 10.1136/jitc-2021-002923. J Immunother Cancer. 2021. PMID: 34285106 Free PMC article.
Immunotherapy of malignant ascites with trifunctional antibodies.
Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Heiss MM, et al. Among authors: lindhofer h. Int J Cancer. 2005 Nov 10;117(3):435-43. doi: 10.1002/ijc.21165. Int J Cancer. 2005. PMID: 15906359
81 results